Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis

Shuji Kanmura, MD, PhD1, Yuko Morinaga, MS1, Akihito Tanaka, MD, PhD1, Yuga Kornaki, MD, PhD1, Hiromichi Iwaya, MD1, Kotaro Kumagai, MD, PhD1, Seiichi Mawatari, MD, PhD1, Fumisato Sasaki, MD, PhD1, Shiro Tanoue, MD, PhD1, Shinichi Hashimoto, MD, PhD1, Yoichi Ono, MD, PhD3, Hidehisa Ohn, MD, PhD3 and Akio Ido, MD, PhD1

INTRODUCTION: DEFA1A3 encodes human neutrophil peptides (HNPs) 1–3 and has multiple copy number variations (CNVs). HNPs are associated with innate immunity. Ulcerative colitis (UC), a chronic inflammatory gastrointestinal disorder, is a life-threatening condition, and predictive markers of UC severity are needed. This study investigated the relationship between DEFA1A3 CNV and UC severity.

METHODS: This study enrolled 165 patients with UC. The relationship between DEFA1A3 CNV and disease severity was analyzed based on Mayo score, patient characteristics, and treatment methods. In addition, serum and stimulated neutrophil-derived HNP concentrations were also measured in patients with high and low DEFA1A3 CNV.

RESULTS: DEFA1A3 CNV was significantly correlated with Mayo score and white blood cell count ($R = 0.46$, $P < 0.0001$; $R = 0.29$, $P = 0.003$, respectively), and only high copy numbers of DEFA1A3 were independent factors for severe UC ($P < 0.001$, odds ratio: 1.88, 95% confidence interval, 1.34–2.61). The number of severe UC patients with high DEFA1A3 CNV was significantly greater than those with low CNV. We confirmed the associations between DEFA1A3 and UC severity using a validation cohort. In addition, the HNP concentration in high-copy number patients was significantly higher after neutrophil stimulation than that in low-copy number patients.

DISCUSSION: This study demonstrated that there is a correlation between DEFA1A3 copy number and severity in patients with UC. In addition, neutrophils from UC patients with higher DEFA1A3 CNV had high reactivity of secretion of HNPs after stimulation. DEFA1A3 CNV may be a novel severity marker and a potential therapeutic target for UC.

Clinical and Translational Gastroenterology 2021;12:e00331. https://doi.org/10.14309/ctg.0000000000000331

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disorder (1). Although the pathogenesis of UC remains unknown, genetic and environmental factors resulting in an immune response to commensal bacteria seem to play a pivotal role in the development of UC. Acute severe UC (ASUC) is a potentially life-threatening condition (2,3). Although approximately half of ASUC patients will respond to intravenous corticosteroid therapy in the short term, about 20% must undergo early colectomy during their first hospital admission. After 1 or more episodes of severe flares, there is a 40% colectomy rate (4,5). Although some standard inflammatory biomarkers correlate well with UC severity, such as C-reactive protein (CRP) and the erythrocyte sedimentation rate (6), predictive markers for the severity of UC are still lacking and highly desirable.

One of the most important pathological hallmarks of UC is the accumulation of neutrophils into the intestinal tissue. Uncontrolled neutrophil infiltration is implicated in the pathogenesis and activity of UC (7,8). Human neutrophil peptides (HNPs), known as alpha-defensins, are secreted and released from active neutrophil granules on activation. HNPs have important immune-modulative functions, which are chemotactic for human monocytes, T cells, and immature dendritic cells (9,10). Our previous study showed that plasma and fecal HNPs in patients with active UC were higher than those in healthy subjects (11,12). It is possible that HNPs are an activity marker of UC, and their concentration may vary widely among patients and may change depending on the handling of blood cells.
Genetic copy number variations (CNVs) are the most common mechanism to achieve structural genetic diversity, playing a key role in human health and in influencing immune responses to viral infection or autoimmune disease (13–16). The expression level of HNPs in neutrophils varies and depends on the CNV of the HNP-encoding gene DEFA1A3, which has an extensive range of copy numbers (17,18). DEFA1A3 CNV may be associated with susceptibility to severe sepsis and hospital-acquired infection (19). However, DEFA1A3 CNV and their involvement in UC development have not been well studied. Here, we investigated whether DEFA1A3 CNVs are related to UC activity and explored HNP expression levels in UC patients depending on the degree of CNV.

METHODS
Study design, setting, and patient identification
In this study, we enrolled UC patients who were treated between 1994 and 2019 at Kagoshima University Hospital (research cohort) and Idzuro Imamura Hospital (validation cohort). Initially, the research cohort sample was examined to establish the number of CNV to discriminate the severity of the disease, and the CNV number in the validation cohort was examined without knowing the Mayo score beforehand. All patients were diagnosed with UC using established endoscopic, radiological, histological, and clinical criteria. Medical records of patients were registered in a prospectively collected inflammatory bowel disease (IBD) database from both hospitals until July 2020. The clinical rating of UC disease activity was based on the Mayo score (20). Disease activity was defined as follows: mild: 3–5 points; moderate: 6–10 points; and severe 11–12 points. ASUC is diagnosed according to Truelove and Witts criteria, which consist of bloody stool frequency ≥6 per day and at least one of the following: pulse rate >90 bpm, temperature >37.8 °C, hemoglobin <10.5 g/dL, and erythrocyte sedimentation rate >30 mm/hr (21). UC patients who underwent total colonoscopy or sigmoidoscopy were included. The Mayo endoscopic score was determined in the most severe region under colonoscopy or sigmoidoscopy observation. Exclusion criteria included patients with a history of total colectomy or colitic cancer, positive for the Clostridoides difficile toxin and pregnancy. The present study was approved by the Kagoshima University Hospital Institutional Review Board and performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the patients who participated in the study.

Samples and DNA extraction
Clinical data and blood samples were obtained from the patients at the time of endoscopy (within 3 days from each other), either in an outpatient or inpatient setting. EDTA-stabilized peripheral whole blood samples were obtained from each patient, and genomic DNA was isolated using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. DNA concentration was measured by spectrophotometry, and samples were stored at −80 °C for analysis.

Droplet digital Polymerase Chain Reaction for DEFA1A3
The primers and probe for the DEFA1A3 assay were Forward: 5’-CCTCTCACTGAGATTG-3’; Reverse: 5’-CCAGCCTGGATT-TATAG-3’; and Probe: 5’-(FAM)CTTGTCCTCGAGCCTT-3’. Bio-Rad’s ddPCR Copy Number Determination Assays (Bio-Rad, Hercules, CA) were used as reference gene.

Genomic DNA was digested with HaeIII (New England Biolabs Japan, Tokyo, Japan) in NEB buffer 0 for 1 hour at 55 °C, followed by 20 minutes at 80 °C. A 22-µL mixture of 2 × ddPCR mastermix (Bio-Rad), forward and reverse primers for target and reference assays (900 nM each), probes for both assays (250 nM each), and 15 ng of digested genomic DNA was prepared and emulsified with Bio-Rad Automated Droplet Generator Oil in Bio-Rad Automated Droplet Generator (Bio-Rad) according to the manufacturer’s instructions. The droplets were automatically transferred to 96-well plates and heat-sealed with Easy Pierce foil sheets. Polymerase chain reaction was performed in a Bio-Rad C1000 thermal cycler with the following cycling parameters: 10 minutes at 95 °C (1 cycle), 30-second denaturation at 94 °C, 1-minute annealing and extension at 58 °C (40 cycles), 10 minutes

Table 1. Clinical characteristics of patients with ulcerative colitis

| Study cohort | No. of patients | Sex | Median age, yr (range) | Median disease duration, yr (range) | Mayo score |
|--------------|----------------|-----|-----------------------|-------------------------------------|-----------|
| Research     | 105            |     | 48.0 (11–87)         | 9.2 (1.3–31.4)                     | 20        |
| Male         | 63 (60)        |     |                       |                                     |           |
| Female       | 42 (40)        |     |                       |                                     |           |
| Validation   | 60             |     | 47.5 (18–74)         | 12.7 (1.4–37.9)                    | 20        |
| Male         | 23 (38.3)      |     |                       |                                     |           |
| Female       |                |     |                       |                                     |           |

Sex

| Extent of disease | Research cohort | Validation cohort |
|-------------------|-----------------|-------------------|
| Rectum            | 4 (3.8)         | 19 (18.1)         |
| Left-sided colitis| 74 (70.5)       | 82 (78.1)         |
| Pancolitis         | 24 (22.8)       |                   |

No. of patients

| Extent of disease | Research cohort | Validation cohort |
|-------------------|-----------------|-------------------|
| Rectum            | 0               | 1 (1.7)           |
| Left-sided colitis| 74 (70.5)       | 18 (30)           |
| Pancolitis         | 24 (22.8)       |                   |

No. of patients

All data are expressed as n (%).
at 98 °C, and a hold at 12 °C. All steps had a ramp rate of 2 °C/s. Droplets were analyzed using a Bio-Rad QX200 Droplet Reader. Fluorescent data from each well were analyzed with QuantaSoft software (v1.7.4; Thermo Fisher, Waltham, MA), where copy number was calculated based on Poisson distribution (22).

**Isolation of human neutrophils from peripheral blood**

Whole blood samples were obtained from patients with UC. Neutrophils were isolated from EDTA-stabilized whole blood using the EasySep Direct Human Neutrophil Isolation Kit (STEMCELL, Vancouver, BC, Canada), according to the manufacturer’s instructions. Cell viability was detected by trypan blue exclusion and exceeded 98%. Neutrophils were maintained in Hanks buffered saline solution supplemented with 10% heat-inactivated fetal bovine serum, sodium pyruvate, 1-mM L-glutamine, 30-μg/mL amphotericin B, 100-μg/mL streptomycin, 100-U/mL penicillin, and 100-μM 2-mercaptoethanol. Cells were counted using a hemocytometer (23).

**Neutrophil activation assay**

Polymorphonuclear neutrophils were adjusted to 1 × 10⁵ cells/mL containing 900 μL of Hanks buffered saline solution, and 100-μL lipopolysaccharide (LPS; 100 ng/mL) was added to each duplicate.

**Figure 1.** The frequencies of DEFA1A3CNV in patients with ulcerative colitis in the research cohort (a) and validation cohort (b). DEFA1A3CNV has a high of 16, low of 3 in the research cohort, and a high of 16, low of 4 in the validation cohort. The median of DEFA1A3CNV in the research and validation cohorts was 7 and 8 copies per diploid genome, respectively. CNV, copy number variation.

**Figure 2.** The correlation between the copy number of DEFA1A3 and various clinical parameters: disease duration, age, and (measured on the most severe day in the observation period) Mayo score, WBC, and CRP. Mayo score and WBC had a significant relationship with the DEFA1A3 copy number by Spearman rank correlation analysis (R = 0.46, P < 0.001; R = 0.29, P = 0.018; respectively). CNV, copy number variation; CRP, C-reactive protein; WBC, white blood cell.
The samples were incubated for 30 minutes in a 37 °C shaking water bath. To end the reaction, 1 mL of ice-cold, 0.1-M phosphate-buffered formaldehyde (10% vol/vol), pH 7.2, was added to each tube. After incubation, the supernatant was collected for enzyme-linked immunosorbent assay (ELISA) (24).

Enzyme-linked immunosorbent assay
HNP defensin peptide concentrations in patient sera and the supernatants of stimulated neutrophils were analyzed using human HNP ELISA kit (Hycult Biotech, Uden, the Netherlands) in duplicate, according to the manufacturer’s instructions. The samples were measured on a plate reader (Model 680 microplate reader; Bio-Rad). The concentration of the respective protein in the plasma was calculated from 450-nm absorbance readings according to a standard curve.

Statistical analysis
Values shown are the mean ± SD. Statistical differences were determined using the Mann-Whitney U test. Univariate analyses were performed using the χ² test for categorical variables and Spearman’s rank correlation analysis. Multivariate analysis was performed using a logistic regression model with the calculation of odds ratios and 95% confidence intervals. Values of P < 0.05 were considered statistically significant. The discriminatory power for each putative marker was described using the receiver operating characteristic area under the curve (ROC-AUC). Statistical analyses were performed using SPSS software (SPSS, Chicago, IL).

RESULTS
Patient characteristics
This study enrolled 105 patients with UC (female/male ratio: 42/63; median age at UC diagnosis: 35 years) as a research cohort. The median disease duration was 9.2 years. Among these patients, 82 had pancolitis, 19 had left-sided colitis, and 4 had proctitis. The median worst Mayo score was 8 (range, 4–12) among patients in the research cohort during observation periods (Table 1).

Distribution of DEFA1A3 copy number in UC patients
The DEFA1A3 copy numbers ranged from 3 to 16 per diploid genome across all UC patients of the research cohort, with a median of 7 copies (Figure 1a). We investigated the relationship between the DEFA1A3 copy number and several parameters: age, duration of disease, Mayo score, white blood cell (WBC) count, and CRP levels on the day when the patient experienced the most severe symptoms. The Mayo score and WBC count were

### Table 2. Clinical characteristics of the patients of the research cohort with severe and nonsevere ulcerative colitis

|                                      | Severe (Mayo = 11 or 12) | Nonsevere (Mayo ≤10) | P    | Multivariate analysis | OR  | 95% CI     | P     |
|--------------------------------------|--------------------------|-----------------------|------|-----------------------|-----|------------|-------|
| No. of patients                      | 24                       | 81                    |      |                       |     |            |       |
| Sex                                  |                          |                       | 0.71 |                       |     |            |       |
| Male                                 | 14 (58.3)                | 49 (60.5)             |      |                       |     |            |       |
| Female                               | 10 (41.7)                | 32 (39.5)             |      |                       |     |            |       |
| Median age, yr (range)               | 52.5 (21–86)             | 46.9 (11–87)          | 0.37 |                       |     |            |       |
| Disease duration, yr (range)         | 8.7 (4–15.4)             | 9.6 (1.3–31.4)        | 0.91 |                       |     |            |       |
| Extent of lesion                     |                          |                       | 0.40 |                       |     |            |       |
| Rectum                               | 0                        | 4 (4.9)               |      |                       |     |            |       |
| Left-sided colitis                   | 3 (12.5)                 | 16 (19.8)             |      |                       |     |            |       |
| Pancolitis                           | 21 (87.5)                | 61 (75.3)             |      |                       |     |            |       |
| Median DEFA1A3 CNV                   | 10 (4–15)                | 7 (4–11)              | <0.001 |                       | 1.88 | 1.34–2.61 | <0.001|
| WBC (average ± SD), μL              | 9,692 ± 4,687            | 7,828 ± 3,527         | 0.065 |                       | 1.01 | 0.99–1.01 | 0.93  |
| CRP (average ± SD), mg/L            | 36.8 ± 53.6              | 22.0 ± 48.6           | 0.03 |                       | 1.07 | 0.95–1.21 | 0.23  |

The severity of ulcerative colitis was defined by Mayo score. All data are expressed as n (%). CI, confidence interval; CNV, copy number variation; CRP, C-reactive protein; OR, odds ratio; WBC, white blood cell.

---

**Figure 3.** The frequencies of **DEFA1A3** CNV were compared between severe and nonsevere UC groups based on Mayo score. The frequencies of **DEFA1A3** CNV in the severe group were significantly higher than that of the nonsevere group (P < 0.001). CNV, copy number variation; UC, ulcerative colitis.
significantly correlated with \( \text{DEFA1A3} \) copy number by Spearman rank correlation analysis (\( R = 0.46, P = 0.001 \); \( R = 0.29, P = 0.003 \), respectively) (Figure 2). No significant differences were observed between the \( \text{DEFA1A3} \) copy number and the other parameters including age, disease duration, and CRP levels (\( R = -0.132, P = 0.21 \); \( R = 0.07, P = 0.53 \); and \( R = 0.021, P = 0.84 \), respectively). In the severe Mayo score group (24 patients), the \( \text{DEFA1A3} \) copy number varied from 4 to 15 copies, with a median number of 10. In the nonsevere group (81 patients), the \( \text{DEFA1A3} \) copy number ranged from 3 to 11, with a median of 7. There were no significant differences in sex, median age, extent of UC lesion, and WBC count between the 2 groups. However, there were significant differences in the distribution of \( \text{DEFA1A3} \) CNV between the 2 groups (Table 2 and Figure 3).

**Prediction of severity of UC based on \( \text{DEFA1A3} \) CNV**

As shown in Table 2, univariate analysis also revealed that the severe UC group had higher \( \text{DEFA1A3} \) CNV, CRP, and WBC compared with the nonsevere group. Therefore, the differences in these 3 parameters in the clinical background of UC patients were subjected to multivariate analysis. The multivariate logistic regression model revealed \( \text{DEFA1A3} \) CNV was a significant independent predictor of severe UC. Patients with higher \( \text{DEFA1A3} \) CNV were associated with an increased risk of higher UC severity (\( P < 0.001 \), odds ratio = 1.88; 95% confidence interval = 1.34–2.61).

**Diagnostic utility of \( \text{DEFA1A3} \) CNV to determine severity of UC**

The ROC-AUCs of WBC, CRP, and \( \text{DEFA1A3} \) CNV for severe UC were 0.607 (95% CI = 0.501–0.754), 0.619 (95% CI = 0.516–0.779), and 0.854 (95% CI = 0.742–0.936) (\( P = 0.045 \), \( P = 0.026 \), and \( P < 0.001 \), respectively). The AUC values of \( \text{DEFA1A3} \) CNV vs WBC and CRP were significantly higher (\( P = 0.004 \) and \( P = 0.015 \), respectively). AUC values of WBC vs CRP were not significantly different (\( P = 0.77 \)). CI, confidence interval; CNV, copy number variation; CRP, C-reactive protein; WBC, white blood cell.
Validation of DEFA1A3 CNV as UC severity predictor

To determine the validity of CNV as a predictor for UC severity, we separately evaluated another patient cohort. Sixty patients with UC participated in the validation cohort. The number of women and men was 23 and 37, respectively; median age at UC diagnosis was 47.5 years, and median disease duration was 12.7 years. The clinical characteristics of the study participants are summarized in Table 1. The DEFA1A3 copy number ranged from 3 to 16 per diploid genome across the patients of the validation cohort, with a median of 7 copies (Figure 1b). The percentage of patients with severe Mayo scores in the high DEFA1A3 CNV group was 42.9% (12 of 28) and that of the low DEFA1A3 CNV group was 18.6% (6 of 32) (Table 4). This difference was statistically significant.

DEFA1A3 CNV of ASUC

Because the number of patients with ASUC was small (7 in the research cohort and 3 in the validation cohort), 10 patients with ASUC were grouped together and compared the patients with non-ASUC. ASUC was diagnosed according to Truelove and Witts criteria during hospitalization. The number of women and men was 4 and 6, respectively; median age at UC diagnosis was 42.7 years (range 15–80 years) in patients with ASUC. All patients had pancolitis type and treated by prednisolone at initially. The median DEFA1A3 copy number of ASUC patients was 10, which was the same median copy number as the severe type based on Mayo score, while the median copy number of non-ASUC patients was 7. The median DEFA1A3 copy number of ASUC was significantly higher than that of non-ASUC. The other parameters including sex and median age were not significantly different between ASUC and non-ASUC patients.

The correlation of serum HNPs and DEFA1A3 CNV in patients with active UC

The serum HNP concentrations in 60 patients in the validation group with UC who provided both serum and DNA samples were measured on the same day. Median serum HNP levels in this subset of patients with UC were 32.7 ng/mL (range, 8.6–124.1 ng/mL). The median serum HNP level of patients in the high DEFA1A3 CNV group was 42.6 ng/mL (n = 28), while those in the low DEFA1A3 CNV group was 33.5 ng/mL (n = 43). The difference in HNP concentrations between the 2 groups was not statistically significant (P = 0.10). In addition, there was no correlation between the copy number of DEFA1A3 and HNP levels (R = 0.19, P = 0.10) (Figure 5a,b).

HNPs expression from neutrophil depends on DEFA1A3 CNV

Neutrophils were isolated from UC patients with high-copy number (n = 4), with copy numbers of 13, 11, 11, and 10, and low-copy number (n = 4), with copy numbers of 5 for all. The
concentration of HNPs in the supernatant that contained active neutrophils was evaluated using ELISA before and after LPS stimulation. Median HNP levels before stimulation in patients in the high- and low-copy number groups were 8.2 ng/mL (range, 3.8–14.3 ng/mL) and 4.8 ng/mL (range, 3.2–9.5 ng/mL), respectively. After stimulation, HNP levels of high- and low-copy number groups were 17.6 ng/mL (range, 11.2–25.2 ng/mL) and 6.9 ng/mL (range, 3.3–13.7 ng/mL), respectively (Figure 6). The HNP levels of each group were significantly increased after LPS stimulation. Notably, the HNP levels were significantly increased (approximately doubled) after stimulation compared with those in the low-copy number group.

DISCUSSION

This study demonstrated that there is a correlation between DEFA1A3 copy number and severity in patients with UC. In addition, neutrophils from UC patients with higher CNV of DEFA1A3 had high HNP secretion after LPS stimulation. Neutrophil infiltration of the mucosa is a common occurrence in UC and thus provides a context for the increased abundance of the neutrophil products such as HNPs in the mucosa of patients with UC. Our previous study showed that neutrophils containing high HNP levels infiltrated the large intestine, thereby intensifying inflammation. Moreover, we demonstrated that high concentrations of HNPs aggravated DSS-induced experimental colitis by elevating the levels of inflammatory cytokines (11,12,25).

HNPs differ in amino acid sequence in only the N-terminal amino acid, which is alanine for HNP-1, aspartate for HNP-3, and truncated/missing in HNP-2. These HNPs, which exhibit potent bactericidal activities against Gram-negative and -positive bacteria, are produced predominantly by neutrophils and are the most abundant neutrophil granule proteins (26,27). HNPs are directly chemotactic for T cells, macrophages, and mast cells. Furthermore, they exert effects on immunomodulatory function by inducing cytokines and chemokines such as tumor necrosis factor (TNF-α) and interleukin (IL)-1β to be produced in monocytes, as well as modulating inflammatory and immune cell activation and migration, leading to damage of surrounding host tissue (28–30). In addition, HNPs attenuate the inhibitory action of dexamethasone on TNF-α production (31). Although HNPs increase production of cytokines in activated monocytes, HNPs were unable to induce TNF-α or IL-1β expression in resting monocytes (9,31–33). HNPs also induce IL-8 production from intestinal epithelial cells in a dose-dependent manner, which may stimulate additional neutrophil accumulation in the intestine (34). HNPs are suggested to play a critical role in the leukocyte-dominant proinflammatory responses in colitis. It is possible that

Table 4. Clinical characteristics of the patients of the validation cohort in the high and low DEFA1A3 CNV groups

|                          | High DEFA1A3 CNV (≥9) | Low DEFA1A3 CNV (≤8) | P     |
|--------------------------|-----------------------|-----------------------|-------|
| No. of patients          | 28                    | 32                    | 0.69  |
| Sex                      |                       |                       |       |
| Male                     | 18 (64.3)             | 19 (59.4)             |       |
| Female                   | 10 (35.7)             | 13 (40.6)             |       |
| Median age, yr (range)   | 54 (23–76)            | 48 (18–77)            | 0.62  |
| Disease duration, yr (range) | 12.2 (3.2–28.5)     | 13.5 (1.4–37.9)       | 0.48  |
| Extent of disease        |                       |                       | 0.31  |
| Rectum                   | 0                     | 1 (3.1)               |       |
| Left-sided colitis       | 6 (21.4)              | 11 (34.4)             |       |
| Pancolitis               | 22 (78.6)             | 20 (62.5)             |       |
| Mayo score               |                       |                       | 0.040 |
| 0–10                     | 16 (57.1)             | 26 (81.3)             |       |
| 11–12                    | 12 (42.9)             | 6 (18.7)              |       |
| Mayo endoscopic score    |                       |                       | 0.068 |
| 0–2                      | 13 (46.4)             | 22 (68.8)             |       |
| 3                        | 15 (53.6)             | 10 (31.2)             |       |
| Immunotherapy history    |                       |                       |       |
| PSL                      | 26 (92.9)             | 27 (84.4)             | 0.19  |
| Azathioprine             | 22 (78.6)             | 18 (56.3)             | 0.067 |
| TNF-α agents             | 9 (32.1)              | 6 (18.8)              | 0.23  |
| Tacrolimus               | 6 (21.4)              | 8 (25)                | 0.74  |
| Surgical operation for colitis | 5 (17.9)         | 1 (3.1)               | 0.058 |

All data are expressed as n (%) except immunotherapy history which is the percentage of total patients in each group.

CNV, copy number variation; PSL, prednisolone, TNF-α, tumor necrosis factor-α.
higher DEFA1A3 CNV facilitates high HNP production, resulting in severe colitis, such as ASUC.

By contrast, several recent independent reports have shown that HNPs have anti-inflammatory properties. HNP-1 reduced IL-1β and TNF-α release from activated human monocytes/macrophages (35,36). Therefore, it is possible that HNPs have a biphasic dose-dependent effect: an amelioration of inflammatory conditions at low concentrations and an aggravation at high ones.

Our previous study and other studies have shown that HNPs act on the purinergic receptor (34). The purinergic receptors are defined adenosine as binding to P1 receptors and ATP as binding to P2 receptors (37). We demonstrated that HNPs induce IL-8 production through P2Y6 through an ERK1/2-dependent mechanism in intestinal epithelial cells (34).

CNV is the most common mechanism underlying structural genetic diversity and plays a key role in human diseases. The copy numbers of the DEFA1A3 gene in the diploid genome are between 5 and 14 in 27 healthy donors from several ethnicities, with a median number of 10 copies (17). Changes in DEFA1A3 copy numbers have been associated with several diseases. A previous study showed that patients with more than 8 copies of DEFA1A3 are more susceptible to severe sepsis (38,39). Patients with lower DEFA1A3 copy numbers (fewer than 7 copies) were far more common to have hospital-acquired infections than controls (19). A lower DEFA1A3 copy number has also been shown to increase the risk of IgA nephropathy and renal dysfunction (40). Patients with Crohn’s disease, particularly with colonic involvement, have a higher DEFA1A3 gene copy number (mean copy number 7.2 vs controls 6.7; P < 0.001) (41). However, another study revealed by quantitative real-time polymerase chain reaction that the median number of DEFA1A3 CNV is 7 in patients with systemic lupus erythematosus. Moreover, no differences in DEFA1A3 CNV were observed between systemic lupus erythematosus patients and controls (42). We suggest that DEFA1A3 CNVs are not disease-
specific markers for IBD but may be used clinically as a predictive marker of severity. Furthermore, previous studies reported that the amount of HNPs expressed in neutrophils was proportional to the combined copy number of DEFA1A3 (17,18). These findings may indicate that lower CNV decreases HNP secretion and such patients are more susceptible to bacterial infections, whereas higher CNV induces HNP secretion and is associated with cell death and inflammatory cytokine production, which may exacerbate inflammation.

Recent studies have disclosed the genetic background of IBD using novel high-throughput technologies such as genomewide association studies. Large-scale international collaborations have contributed to the identification of 200 genetic risk loci for IBD. However, the single nucleotide polymorphisms of DEFA1A3 do not include a risk allele for IBD according to previous reports (43,44). This study found that increased copy number of the HNP-encoding gene DEFA1A3 was a risk factor for severe UC. Neutrophil-borne HNP-1 can synergize with platelets to stimulate monocyte adhesion and enhance their recruitment, thereby participating in acute and chronic inflammation (29). Severe fulminant UC with colonic extensive ulceration causes sepsis-like symptoms (45). Patients with high HNP levels suffer from more severe sepsis because of extensive endothelial barrier dysfunction, and functional blockade of HNPs rescues mice from lethal sepsis (38). Therefore, blockade of HNPs may be a novel mechanism to prevent severe UC.

This study has several limitations. First, although this study was prospective, it enrolled a small number of patients. Therefore, we should examine a larger sample in the near future. Second, there was no correlation between copy number of DEFA1A3 and serum HNP levels. Moreover, there was a nonsignificant trend toward increased HNP levels in the high DEFA1A3 CNV group when compared with the low CNV group. This may be explained by differences in the serum collection timing. We found that stimulated neutrophils in the high DEFA1A3 CNV group resulted in higher HNP secretion. It is suggested that serum HNP levels reflect intestinal HNP concentration by being released from stimulated neutrophils. Therefore, a significant positive correlation would be expected when the serum is collected at the peak of disease severity. Finally, another shortcoming was the lack of long-time follow-up. A prospective observational study is needed to determine the predictive value of DEFA1A3 CNV. This was not possible in the current study because of the small number of patients who underwent surgical operation for colitis (Tables 3 and 4).

In conclusion, we demonstrated that there is a correlation between DEFA1A3 copy number and clinical severity in patients with UC. In addition, neutrophils from UC patients with higher DEFA1A3 CNV had high levels of HNP secretion after stimulation. DEFA1A3 CNV may be a novel severity marker and a potential therapeutic target for UC.

**CONFLICTS OF INTEREST**

**Guarantor of the article:** Shuji Kanmura, MD, PhD.

**Specific author contributions:** S.K.: wrote the manuscript. S.K. and Y.M.: performed the experiments. A.T., Y.K., Y.S., Y.O., and H.O.: collected patient samples. H. I., K.K., S.M., F.S., S.T., S.H., and A.I.: reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

**Financial support:** None to report.

**Potential competing interests:** None to report.

**ACKNOWLEDGMENT**

We would like to thank Editage (www.editage.com) for English language editing.

**Study Highlights**

**WHAT IS KNOWN**

- Copy number variation is associated with disease incidence and drug susceptibility.
- Patients with acute severe ulcerative colitis are more likely to require surgery.
- There are no markers to predict the severity of ulcerative colitis.

**WHAT IS NEW HERE**

- There was a correlation between DEFA1A3 copy number variation and severity in patients with ulcerative colitis.
- The concentration of encodes human neutrophil peptides secreted by neutrophils was positively associated with DEFA1A3 copy number.

**TRANSLATIONAL IMPACT**

- The measurement of DEFA1A3 copy numbers can predict the severity of ulcerative colitis.

**REFERENCES**

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448(7152):427–34.
2. Levy LC, Coburn ES, Choi S, et al. The management of the hospitalized ulcerative colitis patient: The medical-surgical conundrum. Curr Opin Gastroenterol 2020;36(4):265–76.
3. Deiana S, Bagnoli S, Manetti N, et al. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Dig Liver Dis 2016;48(12):1432–7.
4. Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis 2011;5(5):423–9.
5. Brazil JC, Louis NA, Parkos CA. The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis 2013;19(7):1556–65.
6. Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002;97(2):868–9.
7. Territo MC, Ganz T, Selsted ME, et al. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989;84(6):2017–20.
8. Yang D, Chen Q, Chertov O, et al. Human neutrophil defensins selectively chemotact naive T and immature dendritic cells. J Leukoc Biol 2000;68(1):9–14.
9. Kannmura S, Uto H, Numata M, et al. Human neutrophil peptides 1–3 are useful biomarkers in patients with active ulcerative colitis. Inflamm Bowel Dis 2009;15(6):909–17.
10. Kannmura S, Hamamoto H, Morinaga Y, et al. Fecal human neutrophil peptide levels correlate with intestinal inflammation in ulcerative colitis. Digestion 2016;93(4):300–8.
11. Conrad DF, Pinto D, Redon R, et al. Origins and functional impact of copy number variation in the human genome. Nature 2010;464(7289):704–12.
12. Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010;464(7289):713–20.
13. Hu L, Yao X, Huang H, et al. Clinical significance of germline copy number variation in susceptibility of human diseases. J Genet Genomics 2018;45(1):3–12.

**American College of Gastroenterology**

**Clinical and Translational Gastroenterology**

**Increased Gene Copy Number of DEFA1A3**

**INFLAMMATORY BOWEL DISEASE**
16. Machado LR, Ottolini B. An evolutionary history of defensins: A role for copy number variation in maximizing host innate and adaptive immune responses. Front Immunol 2015;6:115.

17. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: Comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005;86(4):423–30.

18. Aldred PM, Hollox EJ, Armour JA. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005;14(14):2045–52.

19. Zhao J, Gu Q, Wang L, et al. Low-copy number polymorphism in DEFA1/DEFA3 is associated with susceptibility to hospital-acquired infections in critically ill patients. Mediators Inflamm 2018;2018:2152650.

20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317(26):1625–9.

21. Truelove SC, Wits LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2(4947):1041–8.

22. Pinheiro LB, Coleman VA, Hindson CM, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 2012;84(2):1003–11.

23. Bai M, Grieshaber-Bouyer R, Wang J, et al. CD177 modulates human neutrophil peptide-1 in ulcerative colitis: A novel role for defensins in intestinal homeostasis: Regulation of IL-1β secretion. J Immunol 2007;179(2):1245–53.

24. Miles K, Clarke DJ, Lu W, et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of α-defensins. J Immunol 2009;183(3):2122–32.

25. Hashimoto S, Uto H, Kanmura S, et al. Human neutrophil peptide-1 modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur J Immunol 2003;33(9):270–20.

26. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3(9):710–9.

27. Lehrer RI, Lu W. Antimicrobial peptides: A new family of innate host defense peptides. Cytokine Netw 2000;11(2):257.

28. Lai Y, Gallo RL. AMPed up immunity: How antimicrobial peptides have function. Trends Immunol 2009;30(3):131–4.

29. Alard JE, Ortega-Gomez A, Wichapong K, et al. Recruitment of classical chemoreceptor regulation. Blood 2017;130(19):2092–100.

30. Wright SD, Ramos RA, Tobias PS, et al. CD 14: A receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249(4975):1431–3.

31. Hashimoto S, Uto H, Kanmura S, et al. Human neutrophil peptide-1 aggravates dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 2012;18(4):667–75.

32. Lehrer RI, Lu W. α-Defensins in human innate immunity. Immunol Rev 2012;245(1):84–112.

33. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3(9):710–9.

34. Ibusuki K, Sakiyama T, Kanmura S, et al. Human neutrophil peptides induce interleukin-8 in intestinal epithelial cells through the P2 receptor and ERK1/2 signaling pathways. Int J Mol Med 2015;35(6):1603–9.

35. Shi J, Aono S, Lu W, et al. A novel role for defensins in intestinal homeostasis: Regulation of IL-1β secretion. J Immunol 2007;179(2):1245–53.

36. Miles K, Clarke DJ, Lu W, et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of α-defensins. J Immunol 2009;183(3):2122–32.

37. Saitoh H, Makoto T, Inoue K. Role of purinergic receptors in CNS function and neuroprotection. Adv Pharmacol 2011;61:495–528.

38. Chen Q, Yang Y, Hou J, et al. Increased gene copy number of DEFA1/DEFA3 worsens sepsis by inducing endothelial pyroptosis. Proc Natl Acad Sci USA 2019;116(8):3161–70.

39. Chen Q, Hakimi M, Wu S, et al. Increased genomic copy number of DEFA1/DEFA3 is associated with susceptibility to severe sepsis in Chinese Han population. Anesthesiology 2010;112(6):1428–34.

40. Ai Z, Li M, Liu W, et al. Low α-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. Sci Transl Med 2016;8(345):345ra86.

41. Jespersgaard C, Fode P, Dybdahl M, et al. Alpha-defensin DEFA1A3 gene copy number elevation in Danish Crohn’s disease patients. Dig Dis Sci 2011;56(12):3517–24.

42. Cheng F, Zhou X, Zhao Y, et al. Alpha-defensin DEFA1A3 gene copy number variation in Asians and its genetic association study in Chinese systemic lupus erythematosus patients. Gene 2013;517(2):158–63.

43. Momozawa Y, Dmitrieva J, Thomé E, et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun 2018;9(1):2427.

44. Liu JZ, Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47(9):979–86.

45. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14(12):1660–6.

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.